Talking About Tumors with Ryann and Ryan - A medical oncology podcast

02_07 HER-2 positive breast cancer: Considerations in advanced disease

January 19, 2023 Talking About Tumors Season 2 Episode 7
02_07 HER-2 positive breast cancer: Considerations in advanced disease
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
More Info
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
02_07 HER-2 positive breast cancer: Considerations in advanced disease
Jan 19, 2023 Season 2 Episode 7
Talking About Tumors

1. Anti-HER2 agent classes
2. Cleopatra Trial
3. Later line options
4. Leptomeningeal carcinomatosis 

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101

3.          Baselga J et al. NEJM. 2012;366(2):109-119. doi:10.1056/NEJMOA1113216/

4.          Swain SM et al. NEJM. 2015;372(8):724-734. doi:10.1056/NEJMOA1413513/

5.          Verma S  et al. T. NEJM. 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124/

6.          Cortés J et al. NEJM. 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022/

7.          Krop IE et al. Lancet Oncol. 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-3

8.          Murthy RK et al. NEJM. 2020;382(7):597-609. doi:10.1056/NEJMOA1914609/

 

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Show Notes

1. Anti-HER2 agent classes
2. Cleopatra Trial
3. Later line options
4. Leptomeningeal carcinomatosis 

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101

3.          Baselga J et al. NEJM. 2012;366(2):109-119. doi:10.1056/NEJMOA1113216/

4.          Swain SM et al. NEJM. 2015;372(8):724-734. doi:10.1056/NEJMOA1413513/

5.          Verma S  et al. T. NEJM. 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124/

6.          Cortés J et al. NEJM. 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022/

7.          Krop IE et al. Lancet Oncol. 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-3

8.          Murthy RK et al. NEJM. 2020;382(7):597-609. doi:10.1056/NEJMOA1914609/

 

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology